Catalyst
Slingshot members are tracking this event:
Pfizer's' (PFE) Xeljanz Approved in China for Treatment of Adults With Moderate-to-Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response or are Intolerant of Methotrexate (MTX)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PFE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 15, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Xeljanz, China, Adults, Moderate-to-severe, Active Rheumatoid Arthritis, Methotrexate
